AMP Capital Investors’s PDL BioPharma, Inc. PDLI Stock Holding History

AMP Capital Investors’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-46,268	Closed	-$150K	–	1279
2019 Q4	$150K	Buy	+46,268	New	+$134K	﹤0.01%	1155
2017 Q2	–	Sell	-41,114	Closed	-$89K	–	1259
2017 Q1	$89K	Hold	41,114	–	–	﹤0.01%	1180
2016 Q4	$87K	Hold	41,114	–	–	﹤0.01%	1200
2016 Q3	$133K	Buy	+41,114	New	+$131K	﹤0.01%	1212
2015 Q1	–	Sell	-113,472	Closed	-$875K	–	1248
2014 Q4	$875K	Hold	113,472	–	–	0.01%	910
2014 Q3	$860K	Hold	113,472	–	–	0.01%	922
2014 Q2	$1.1M	Sell	113,472 -200	-0.2%	-$1.78K	0.01%	891
2014 Q1	$908K	Sell	113,672 -91,677	-45%	-$786K	0.01%	895
2013 Q4	$1.74M	Buy	205,349 +36,149	+21%	+$305K	0.01%	753
2013 Q3	$1.39M	Buy	169,200 +8,200	+5%	+$65.9K	0.01%	782
2013 Q2	$1.24M	Buy	+161,000	New	+$1.26M	0.01%	852

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ECM

Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AMP Capital Investors's PDLI Position: Q1 2020 in Review

AMP Capital Investors sold out of PDL BioPharma, Inc. (PDLI) in Q1 2020, closing a stake of 46,268 shares — an estimated $150K sold.

AMP Capital Investors first reported a position in PDLI in Q2 2013 and held it in 11 quarters. The position peaked at $1.74M in Q4 2013. 133 funds tracked by Wall St. Rank hold PDLI as of Q1 2020.

AMP Capital Investors reported no remaining PDL BioPharma, Inc. position as of Q1 2020 after selling out during the quarter.
AMP Capital Investors sold 46,268 PDL BioPharma, Inc. shares in Q1 2020, an estimated $150K.
AMP Capital Investors first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 11 quarters.
AMP Capital Investors's PDL BioPharma, Inc. position peaked at $1.74M in Q4 2013.
133 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2020.

Based on AMP Capital Investors's 13F filing for Q1 2020, filed 13 May 2020.